Promoting acute thrombolysis for ischaemic stroke (PRACTISE)

International Journal of Stroke

Volumn 2, Issue 2, 2007, Pages 151-159

  Dirks, Maaike ^a   Niessen, Louis W ^a   Huijsman, Robbert ^a   Van Wijngaarden, Jeroen ^a   Minkman, Mirella M N ^b   Franke, Cees L ^c,d   van Oostenbrugge, Robert J ^e   Koudstaal, Peter J ^a   Dippel, Diederik W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Dutch Institute for Healthcare Improvement CBO   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d Netherlands Heart Foundation   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DISABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

FIBRINOLYTIC AGENTS; HUMANS; RESEARCH DESIGN; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34247887746     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2007.00119.x     Document Type: Article

References (40)

1. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003; 3; CD000213.
2. Adams H, Adams R, Del ZG, Goldstein LB: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-23.
3. Hacke W, Kaste M, Bogousslavsky J et al. European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis 2003; 16: 311-37.
4. Grotta JC, Burgin WS, El Mitwalli A et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001; 58: 2009-13.
5. Franke CL, Franke-Barendse EAM, Dercksen A, Stolker D: Substantial knowledge on stroke after a campaign. Hart Bull 2000; 1: 14-8.
6. Scholte Op Reimer WJ, Dippel DW, Franke CL et al. Quality of hospital and outpatient care after stroke or transient ischemic attack. Insights from a stroke survey in the Netherlands. Stroke 2006; 37: 1844-9.
7. Meijer RJ, Hilkemeijer JH, Koudstaal PJ, Dippel DWJ: Modifiable determinants of delayed hospital admission following a cerebrovascular accident. Ned Tijdschr Geneeskd 2004; 148: 227-31.
8. Boode B, Welzen V, Franke C, van Oostenbrugge R: Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis 2006; 23: 294-8.
9. Schenkel J, Weimar C, Knoll T et al. R1 -systemic thrombolysis in German stroke units -the experience from the German Stroke data bank. J Neurol 2003; 250: 320-4.
10. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM: Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004; 61: 346-50.
11. Van Breda EJ, Dirks M, Scholte op Reimer W, Hoeks S, Dippel DWJ: Is thrombolysis an underused treatment for acute ischemic stroke? Cerebrovasc Dis 2005; 19: 113-4.
12. Kwan J, Hand P, Sandercock P: A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 2004; 33: 116-21.
13. Qureshi AI, Kirmani JF, Sayed MA et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005; 64: 2115-20.
14. Casetta I, Granieri E, Gilli G, Lauria G, Tola MR, Paolino E: Temporal trend and factors associated with delayed hospital admission of stroke patients. Neuroepidemiology 1999; 18: 255-64.
15. Evenson KR, Rosamond WD, Morris DL: Prehospital and in-hospital delays in acute stroke care. Neuroepidemiology 2001; 20: 65-76.
16. Feldmann E, Gordon N, Brooks JM et al. Factors associated with early presentation of acute stroke. Stroke 1993; 24: 1805-10.
17. Rosamond WD, Gorton RA, Hinn AR, Hohenhaus SM, Morris DL: Rapid response to stroke symptoms: The Delay in Accessing Stroke Healthcare (DASH) study. Acad Emerg Med 1998; 5: 45-51.
18. Ingall TJ, O'Fallon WM, Asplund K et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment Trial. Stroke 2004; 35: 2418-24.
19. Bell DE: Regret in decision making under uncertainty. Oper Res 1982; 30: 961-81.
20. Bell DE: Disappointment in decision making under uncertainty. Oper Res 1985; 33: 1-27.
21. Leape LL, Kabcenell AI, Gandhi TK, Carver P, Nolan TW, Berwick DM: Reducing adverse drug events: Lessons from a breakthrough series collaborative. Jt Comm J Qual Improv 2000; 26: 321-31.
22. Flamm BL, Berwick DM, Kabcenell A: Reducing cesarean section rates safely: Lessons from a 'breakthrough series' collaborative. Birth 1998; 25: 117-24.
23. Kilo CM: Improving care through collaboration. Pediatrics 1999; 103: 384-93.
24. Berwick DM: CrossCng the boundary: changing mental models in the service of improvement. Int J Qual Health Care 1998; 10: 435-41.
25. Minkman MM, Schouten LM, Huijsman R, van Splunteren PT: Integrated care for patients with a stroke in the Netherlands: Results and experiences from a national Breakthrough Collaborative Improvement project. Int J Integr Care 2005; 5: E14.
26. Moher D, Schulz KR, Altman D: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-91.
27. Campbell MK, Elbourne DR, Altman DG: CONSORT statement: extension to cluster randomised trials. BMJ 2004; 328: 702-8.
28. Fiander M, Burns T, McHugo GJ, Drake RE: Assertive community treatment across the Atlantic: Comparison of model fidelity in the UK and USA. Br J Psychiatry 2003; 182: 248-54.
29. van Exel NJ, Koopmanschap MA, Scholte op RW, Niessen LW, Huijsman R: Cost-effectiveness of integrated stroke services. QJM 2005; 98: 415-25.
30. Ehlers L, Andersen G, Clausen LB, Bech M, Kjolby M: Cost-Effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke. Stroke 2007; 38: 85-9.
31. Fagan SC, Morgenstern LB, Petitta A et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998; 50: 883-90.
32. Mar J, Begiristain JM, Arrazola A: Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005; 20: 193-200.
33. Sandercock P, Berge E, Dennis M et al. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004; 35: 1490-7.
34. Kerry SM, Bland JM: Statistics notes: Sample size in cluster randomisation. BMJ 1998; 316: 549.
35. Kerry SM, Bland JM: Statistics notes: The intracluster correlation coefficient in cluster randomisation. BMJ 1998; 316: 1455-60.
36. van Houwelingen JC: [Roaming through methodology. III. Randomization at the level of the physicians]. Ned Tijdschr Geneeskd 1998; 142: 1662-5.
37. Wardlaw J, Berge E, del Zoppo G, Yamaguchi T: Thrombolysis for Acute Ischemic Stroke. Stroke 2004; 35: 2914-5.
38. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Recombinant tissue plasminogen activator for minor strokes. Ann Emerg Med 2005; 46: 243-52.
39. Eccles M, Grimshaw J, Campbell M, Ramsay C: Research design for studies evaluating the effectiveness of change and improvement strategies; in Grol R, Baker R, Moss F (eds): Quality improvement research: understanding the science of change in health care. London: BMJ Books, 2004: 97-114.
40. Niessen LW, Barendregt JJ, Bonneux L, Koudstaal PJ: Stroke trends in an aging population. The Technology Assessment Methods Project Team. Stroke 1993; 24: 931-9.